Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 801–900 of 1,000
Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer
Barot, S. V., Roesch, E. E., & Abraham, J. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2146580 · Cited by 5
“9% vs 1%) of ≥ grade 3 were more common in the tucatinib group than in the placebo group[55].”
BackgroundCáncer de mama HER2-positivo: Terapias Sistémicas Actuales y Experiencia Local
Walbaum, B., Francisco Acevedo, C., Diego Carrillo, B., Mauricio Camus, A., Manzor, M., Raul Martínez, R., Veglia, P., Murature, G., Valentina Salvado, U., Muñiz, S., et al. (2023) · Revista de Cirugía · doi:10.35687/s2452-454920230011653 · Cited by 4
Shayan, S., Osgoei, L. T., & Jouni, F. J. (2023) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v22i7.5 · Cited by 4
“On the other hand, capecitabine is a drug used to treat various cancers, including breast cancer [13].”
BackgroundNew Concepts in Cardio-Oncology
Zagami, P., Nicolò, E., Corti, C., Valenza, C., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_12 · Cited by 4
Self-citationHijazi, A., Mohanna, M., Sabbagh, S., Herrán, M., Dominguez, B. G., Sarna, K., & Nahleh, Z. A. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07321-x · Cited by 4
“…Deruxtecan [30], and Per-tuzumab [31]; tyrosine kinase inhibitors including: Lapatinib [32–35], Neratinib [36–38], Afatinib [39], Tucatinib [40], Taselisib [41], Alpelisib [42], Buparlisib [43]; and CDK 4/6 inhibitors including: Palbociclib [44], Ribociclib [45], and Abemaciclib [46];…”
BackgroundUpdates in HER2-Positive and Triple-Negative Breast Cancers
Telli, M. L., & Gradishar, W. J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.5005 · Cited by 4
“0074) at the first interim analysis.(8) Risk of disease progression or death was reduced by 46% in the”
BackgroundJohnson, K. C., Quiroga, D. M., Sudheendra, P. K., & Wesolowski, R. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2063844 · Cited by 5
Brain Metastasis in Breast Cancer Patients—Need for Improvement
Witzel, I., Oliveira‐Ferrer, L., & Müller, V. (2020) · Cancers · doi:10.3390/cancers12113190 · Cited by 4
“With an increasing attention to the high clinical need for better evidence, some trials specifically allowed the inclusion of patients with active BM [6,7], and we hope to see more data from randomized trials in the future.”
BackgroundSelf-citationLin, N. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1391 · Cited by 4
Self-citationMoscardini-Martelli, J., Rodríguez-Camacho, A., Torres-Ríos, J. A., Meraz-Soto, J. M., Flores-Vázquez, J. G., Hernández-Sánchez, L. C., Lozano-Ruiz, F. J., Maldonado‐Magos, F., Cid-Sánchez, D. R., Flores-Balcázar, C. H., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100658 · Cited by 4
“According to the results of the HER2CLIMB trial, tucatinib, a selective HER2 tyrosine kinase inhibitor, along with trastuzumab and capecitabine, may be advantageous for patients with metastatic breast cancer who have received a lot of prior treatment [40].”
BackgroundChew, S. M., Ferraro, E., Chen, Y., Barrio, A. V., Kelly, D., Modi, S., Seidman, A. D., Wen, H. Y., Brogi, E., Robson, M. E., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00631-9 · Cited by 3
“…studied in the HER2CLIMB trial and showed an improved OS of 21.9 months in the tucatinib/trastuzumab/ capecitabine group versus 17.4 months in the placebo/ trastuzumab/ capecitabine group (Hazard ratio 0.66, 95% con fi dence interval (CI) 0.50 – 0.88, p = 0.005) for MBC patients with BM 18 .”
BackgroundInfluentialPodder, V., Bellur, S. S., Margolin, K. A., Advani, P. P., Mahtani, R. L., Subbiah, V., Novo, G. B., Ranjan, T., & Ahluwalia, M. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01593-8 · Cited by 5
“In the landmark phase II HER2CLIMB trial, tucatinib combined with trastuzumab and capecitabine significantly improved PFS and OS outcomes for heavily pretreated HER2 + advanced breast cancer patients at a median follow-up of 29.6 months [89].”
InfluentialOligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease?
Zouki, D. N., Karatrasoglou, E. A., Pilichos, G., & Papadimitraki, E. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01275-4 · Cited by 3
“The remarkable CNS response to these new therapies can allow us to delay or even avoid invasive techniques in selected cases [32–34].”
Barco, S. D., Cotes, A., Cavanagh, M., Sarrió, R. G., Vicente, B. L. D. S., Galve-Calvo, E., & Servitja, S. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03838-1 · Cited by 3
“In those patients ≥ 65 years with central nervous system metastases, the benefit was comparable although their representation was small [47, 48].”
Discovery of isoquinoline-tethered quinazoline derivatives with enhanced HER2 inhibition over EGFR
Lee, J. W., Im, C. G., Lee, J. M., Cho, M., Kim, M. G., Lee, K., Nguyen, H. T. T., Seo, J., Seo, J. H., & Min, K. H. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00025d · Cited by 3
Camera, S., Rimini, M., Foti, S., Prinzi, F. L., Vitiello, F., Amadeo, E., Persano, M., Cascinu, S., Gardini, A. C., & Rossari, F. (2025) · Oncology · doi:10.1159/000545308 · Cited by 4
Kesireddy, M., Masih, D., Shostrom, V., Yellala, A., Asif, S., & Krishnamurthy, J. (2025) · Cancers · doi:10.3390/cancers17111823 · Cited by 5
Jourdain, H., Meglio, A. D., Mansouri, I., Desplas, D., Zureik, M., & Haddy, N. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101455 · Cited by 3
“37”
Das, S., Satapathy, B. S., Pattnaik, G., Pattanaik, S., Alhamhoom, Y., Rahamathulla, M., Ahmed, M. M., & Pasha, I. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s541332 · Cited by 3
“15 Nanodrug carriers like nanoliposomes, polymeric nanoparticles, polymeric micelles, solid-lipid nanoparticles, dendrimers, niosomes, metallic nanocarriers etc., have opened promising avenues to modulate therapeutic effects of conventional chemotherapy.”
Antibody-drug conjugates in oncology: A spotlight on overcoming resistance
Xu, X., Yu, T., & Wang, Z. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105015 · Cited by 7
Martín-Quesada, A. I., & Martín-Abreu, C. M. (2026) · Seminars in Oncology · doi:10.1016/j.seminoncol.2026.152466 · Cited by 5
Yamamoto, Y. (2026) · Cancers · doi:10.3390/cancers18060932 · Cited by 4
“Clinical benefits were established in the HER2CLIMB trial [102].”
Lu, Y., Lee, B. P., Eli, A. V., Lynch, S. E., Faisal, A.-R. M., Moye, J. A., & Sorace, A. G. (2026) · Cancers · doi:10.3390/cancers18060997 · Cited by 3
“Additionally, the use of two HER2-targeting agents, trastuzumab and tucatinib, mirrors approaches being investigated clinically, with the HER2Climb clinical trial demonstrating the effectiveness of this combination [42,43].”
Lipid Metabolism and Breast Cancer Therapy: An Integrative Literature Review
Gong, X., Zhang, D. H., Wen, Z., Zeng, J., Tang, Y., Deng, J., & Bin, Y. (2026) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s575419 · Cited by 3
“26,27 In recent years, metabolic abnormalities have also been identified as another important mechanism of endocrine resistance, among which lipid metabolism is included.”
Miles, R. C., Nicolae, A., & Ravi, A. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3506.0320 · Cited by 3
A Concise Review on Tyrosine Kinase Targeted Cancer Therapy
Shah, A. P., Patel, C. N., Parmar, G. R., Patel, A. D., & Jain, M. (2022) · Current Drug Therapy · doi:10.2174/1574885517666220331104025 · Cited by 3
Zhou, S., Zhang, L., Xue, S., Wang, Y., & Ding, R. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0559 · Cited by 3
“The HER2-specific tyrosine kinase inhibitor tucatinib had a survival benefit in the treatment of BM when used in combination with trastuzumab and capecitabine [38].”
BackgroundEffect of Tucatinib on Cardiac Repolarization in Healthy Volunteers
Topletz‐Erickson, A. R., Mayor, J. G., Liu, H.-T., Abdulrasool, L. I., & Endres, C. J. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00440-8 · Cited by 3
“…(approved dose of 300 mg twice daily) added to trastuzumab and capecitabine significantly prolonged progression-free survival (including in patients with brain metastases) and overall survival in patients who had previously received trastuzumab, pertuzumab, and trastuzumab emtansine [6, 7].”
BackgroundBreast Cancer Brain Metastases: Achilles’ Heel in Breast Cancer Patients’ Care
Ferraro, E., & Seidman, A. D. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_11 · Cited by 3
Pratiwi, M. R. E., Sasmito, P., & Kase, M. T. P. (2023) · Journal of World Future Medicine Health and Nursing · doi:10.55849/health.v1i2.433 · Cited by 3
A Biophysical Study of Molecular Interaction of Tucatinib with Bovine Serum Albumin
Jalan, A., & Moyon, N. S. (2024) · ChemistrySelect · doi:10.1002/slct.202402600 · Cited by 3
Current approaches to the pharmacological management of metastatic breast cancer in older women
Carmona-Gonzalez, C. A., Kumar, S., & Menjak, I. B. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2402022 · Cited by 3
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments
Belluzzi, L., Martinelli, G., Medici, B., Farina, A., Martinelli, E., Canino, F., Caggia, F., Molinaro, A., Barbolini, M., Tamburrano, F., et al. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s489419 · Cited by 5
Miao, H., Ye, T., Liu, M., Gao, J., Tan, L., Dong, Q., Lv, Q., Ye, Q., & Wang, Y. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202508310 · Cited by 4
Chakraborty, S., & Banerjee, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03090-1 · Cited by 3
“When combined with Trastuzumab and Capecitabine [52], Neratinib works against nausea, diarrhoea, fatigue and overexpressed aminotransferase.”
Etirinotecan Pegol ( NKTR ‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
Nagpal, S., Nguyen, K.-S. H., Bertrand, S., Cunanan, K. M., Padda, S. K., Pagtama, J. Y., Tisch, A. H., Coffey, G., Thomas, R. P., Sledge, G. W., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70330 · Cited by 3
Self-citationHER2-positives und metastasiertes Mammakarzinom: Standards und neue Entwicklungen
Fehm, T. N., & Müller, V. (2020) · Der Onkologe · doi:10.1007/s00761-020-00724-7 · Cited by 3
Self-citationTargeting molecular subtypes in solid cancers: successes and failures
Assi, R. E., Kotecki, N., & Awada, A. H. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000670 · Cited by 3
Brain metastases: new systemic treatment approaches
Steindl, A., & Berghoff, A. S. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00709-1 · Cited by 3
Value of Geriatric Assessment in Patients With Genitourinary Carcinoma
Zangl, Q., Wirth, J., Karl, A., Stief, C. G., Zwißler, B., & von Dossow, V. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0620 · Cited by 3
Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines
Feng, Q., Yu, X., Wang, Y., Li, S., & Yang, Y. (2021) · RSC Advances · doi:10.1039/d1ra06146a · Cited by 3
Mallet, A., de Calbiac, O., Robert, M., Campone, M., & Frenel, J. (2021) · Bulletin du Cancer · doi:10.1016/s0007-4551(21)00633-0 · Cited by 4
Piña, Y., Gramatzki, D., Forsyth, P. A., Lee, E. Q., & Rhun, É. L. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.009 · Cited by 3
Oki, N., Seki, H., Sakurai, T., Horiuchi, Y., Kodaka, K., & Shimizu, K. (2022) · Breast Disease · doi:10.3233/bd-210032 · Cited by 3
Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities
Talele, S., Mohammad, A. S., Schulz, J., Bauer, B., Hartz, A. M. S., Sarkaria, J. N., & Elmquist, W. F. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_24 · Cited by 3
Denduluri, N., Espirito, J. L., Hackshaw, M. D., Wentworth, C., Recchia, T., & Kwong, W. J. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00340-4 · Cited by 3
“tucatinib led to improved survival in patients with brain metastases [18, 19, 24].”
BackgroundEbrahimnejad, P., Mohammadi, Z., Ahmadi, M., Amirkhanloo, S., Babaei, A., Asare‐Addo, K., & Nokhodchi, A. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022043898 · Cited by 3
Simion, L., Augustin, I. G., Volovăț, S. R., Froicu, E.-M., Schenker, M., Mazilu, L., Niţipir, C., Zivari, M., Volovat, C. D., Alecu, M., et al. (2022) · Archives of Breast Cancer · doi:10.32768/abc.202310115-25 · Cited by 3
Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis
Wu, S., Liu, Y., Zhou, J., You, Y., Zhou, X., Chen, L.-Q., Kwan, H. Y., Zhao, X., Wu, Y.-F., & Liu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1091249 · Cited by 3
“The first clinical trial was the phase II trial of tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer (15), earning the most attention of researchers in the related field (burst strength: 55.”
BackgroundInfluentialShi, W., Li, Y., Sun, H., Zhang, L., Meng, J., Wang, X., Chen, X., Zhang, X., Mei, X., Ma, J., et al. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02293-6 · Cited by 3
Theriault, B. C., Singh, C., Yu, J. B., Knisely, J. P. S., Shepard, M. J., Wegner, R. E., Warnick, R. E., Peker, S., Samancı, Y., Trifiletti, D. M., et al. (2023) · Cureus · doi:10.7759/cureus.45457 · Cited by 3
Yazdanpanah, O., Lee, F.-C., Houshyar, R., Nourbakhsh, M., & Mar, N. (2024) · SAGE Open Medical Case Reports · doi:10.1177/2050313x231223469 · Cited by 3
“23,24 Tucatinib is a tyrosine kinase inhibitor that targets both ERBB2 (HER2) and ERBB3 (HER3), which has shown efficacy in treatment of HER2-positive unresectable or metastatic breast 29,30 and colorectal cancer.”
BackgroundVarghese, D., Cruz, G., Johanson, C., Toland, L., Miranda, M., Faherty, E. C., Harland, D., & Kaplan, H. G. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02492-5 · Cited by 3
“For the overall study population, rwPFS of 7.9 months was within the range of results of 3 to 10 months reported in clinical trials conducted among previously treated patients in the metastatic setting [15, 17, 19, 38–40].”
ResultInfluentialChen, Y., Zhang, T., Zhang, R., & Cao, X. B. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0175 · Cited by 3
Recent advances in breast cancer metastasis with special emphasis on metastasis to the brain
Sadique, F. L., Subramaiam, H., Krishnappa, P., Chellappan, D. K., & Hao, J. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155378 · Cited by 3
Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases
Asazuma, K., Shimomura, A., Kawamura, Y., Taniyama, T. K., & Shimizu, C. (2024) · Case Reports in Oncology · doi:10.1159/000540257 · Cited by 3
“…Kinase 2 (ERBB2)-positive breast cancer brain metastases (BCBM), the ef fi cacy of tucatinib in combination with trastuzumab and capecitabine [2], as well as lapatinib combined with capecitabine [3], has been reported; however, effective treatment options for ERBB2-negative BCBM are limited.”
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Trembath, H. E., Yeh, J. J., & Lopez, N. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_15 · Cited by 3
Guidelines about radiotherapy and oncologic systemic treatments: Stop or continue?
Buchalet, C., Golfier, C., Faivre, J.-C., Azria, D., Kirova, Y., Lapierre, A., Latorzeff, I., Mirjolet, C., Hennequin, C., Leroy, T., et al. (2025) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2025.104757 · Cited by 3
Hartkopf, A. D., Emons, J., Lux, M. P., Taran, F., Overkamp, F., Tesch, H., Titzmann, A., Pöschke, P., Lüftner, D., Wallwiener, M., et al. (2020) · Der Onkologe · doi:10.1007/s00761-020-00766-x · Cited by 3
Self-citationFrontiers in HER2-positive breast cancer in 2020
Peddi, P. F., & Slamon, D. J. (2020) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000677 · Cited by 3
Self-citationActivity of novel anti-HER2 agents for breast cancer based on hormone receptors expression
Tarantino, P., & Curigliano, G. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06150-6 · Cited by 3
“This scenario has recently been revolutionized by the emergence and FDA approval of a multiplicity of novel anti-HER2 agents, including the antibody-drug conjugate trastuzumab deruxtecan [1], the tyrosine-kinase inhibitors tucatinib [2] and neratinib [3], and the FC-engineered monoclonal antibody margetuximab [4].”
BackgroundSelf-citationErickson, A. W., Habbous, S., Hoey, C., Jerzak, K. J., & Das, S. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00220-0 · Cited by 3
Chen, I., Hu, F., Lin, C., Huang, S., Chang, D., Cheng, A., & Lu, Y. (2021) · The Breast · doi:10.1016/j.breast.2021.07.006 · Cited by 3
Nouvelles stratégies thérapeutiques dans les cancers du sein HER2-surexprimé
Méry, B., Toussaint, P., Heudel, P., Dufresne, A., Carbonnaux, M., Vanacker, H., Bachelot, T., & Trédan, O. (2021) · Bulletin du Cancer · doi:10.1016/s0007-4551(21)00632-9 · Cited by 3
Self-citationMcAndrew, N. P., & Hurvitz, S. A. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.012 · Cited by 3
Self-citationBartsch, R., & Preusser, M. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae202 · Cited by 3
New Enhancing Oncology Model builds on knowledge from the OCM
Staggs, S. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89229 · Cited by 2
He, J., & Jia, Y. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-66 · Cited by 2
“Pertuzumab (HER2 targeted monoclonal antibody) (23), lapatinib (HER1 and HER2 tyrosine kinase inhibitor) (24), neratinib (HER tyrosine kinase inhibitor) (25), tucatinib (HER2 tyrosine kinase inhibitor) (26), trastuzumab emtansine (27) and trastuzumab deruxtecan (28) (antibody drug conjugate) were the currently availab…”
BackgroundNingsih, D. M., Firmansyah, M. T., & Wawo, B. A. M. (2023) · Journal of World Future Medicine Health and Nursing · doi:10.55849/health.v1i1.431 · Cited by 2
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies
Lee, J., & Ku, G. Y. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001043 · Cited by 2
Atrial Fibrillation in Patients with Breast Cancer: A Literature Review
Bello, M. O., Wadid, M., Malode, A., Patel, V., Shah, A. S., Vyas, A., Ahmad, H. A., Tarun, T., Dani, S. S., Ahmad, J., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00394-1 · Cited by 2
“…DOACs have fewer DDI than warfarin and have also been shown to have fewer bleeding events, apixaban and rivaroxaban are metabolized by CYP3A4 and interfere with certain anticancer treatments such as tucatinib, an anti-HER2 tyrosine kinase inhibitor, possibly by decreasing their levels [7, 41, 64].”
Al-sultan, S., Mohammed, M. H., & Talib, W. H. (2024) · Turkish computational and theoretical chemistry/Turkish computational and theoretical chemistry : · doi:10.33435/tcandtc.1534907 · Cited by 2
Ajjawi, I., Ríos-Hoyo, A., Wei, W., Park, T. S., & Lustberg, M. B. (2025) · Cancers · doi:10.3390/cancers17091579 · Cited by 2
Ring, A. E., Sutherland, S., Harper-Wynne, C. L., Owen, J., Sanglier, T., & Velikova, G. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07708-4 · Cited by 2
“However, over the last few years a number of systemic therapies with activity against brain metastases have been identified, including tucatinib, an oral selective inhibitor of the HER2 tyrosine-kinase [14], and the antibody–drug conjugate Trastuzumab-Deruxtecan [15].”
Anders, C. K., Neuberger, E. E., Schwartz, N. R. M., Bartley, K., Wang, S., Liu, Y., Pittner, B. T., Kaufman, P. A., & Meisel, J. L. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02800-7 · Cited by 3
“This real-world analysis utilizing data from two nationwide claims databases, MarketScan ® and Komodo ™ , reinforces previously published real-world evidence [19] and results from the pivotal HER2CLIMB trial [13].”
InfluentialSelf-citationTaiwo, R., Harary, P. M., Trinh, T. T. H., Granucci, M., Bertrand, S., Carlson-Clarke, B., Chernikova, S. B., Therkelsen, K. E., Arora, M., Melisko, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14282-x · Cited by 2
“Although a combination of tucatinib, trastuzumab, and capecitabine improved PFS in patients with HER2-positive BrM [32], median PFS was only 7 months and patients with LMD were excluded.”
Dung, N. P., Kim, H. K., Huyen, V. T. M., Kang, D. H., Kim, H. Y., Kang, J. S., Anh, D. T., Tùng, T. T., Han, S., & Nam, N. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143653 · Cited by 3
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
Parsons, H. A., Messer, C., Santos, K., Weiss, J., Merrell, D., Danysh, B. P., Hughes, M. E., Kirkner, G. J., Patel, A., Hess, J. M., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100987 · Cited by 2
Self-citationThe use of granulocyte colony-stimulating factors in the management of breast cancer patients
Bałata, A., Szombara, E., Nowecki, Z. I., & Pogoda, K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613199 · Cited by 2
Zhou, Q., Li, Y., He, N., Zou, G., Ni, M., Zhang, L., Dun, S., Chen, Z., Liu, K., Cao, Y., et al. (2025) · Cancer Science · doi:10.1111/cas.70181 · Cited by 2
Korantzis, I., Koumarianou, A., Rapti, V., Timotheadou, E. T., Christodoulou, C., Tryfonopoulos, D. J., Karageorgopoulou, S., Boukovinas, I., Zagouri, F., Nikolaidi, A., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14791-9 · Cited by 2
“…patients previously treated with more than two anti-HER2 regimens, showing positive results in the phase II trial HER2CLIMB, particularly in the subgroup of patients with untreated or progressing brain metastases (BMs) who were until recently excluded from interventional clinical trials [17, 18].”
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)
García-Sáenz, J. Á., Blancas, I., Echavarría, I., Hinojo, C., Vila, M. M., Antón, F. M., Pernas, S., y Cajal, T. R., Ribelles, N., & Bellet, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04102-w · Cited by 5
“In a randomized trial that included heavily pretreated patients (median of four prior lines of therapy, but no prior T-DXd), PFS and OS rates were superior in patients receiving tucatinib–trastuzumab–capecitabine to those in patients receiving capecitabine–trastuzumab only [75].”
Drittone, D., Lucci, C., Esposito, L., Mazzuca, F., & Pisegna, S. (2025) · Cancers · doi:10.3390/cancers17213520 · Cited by 3
“…who experienced isolated CNS progression and continued on study-assigned treatment after local intervention demonstrated a prolonged median time to second progression (either intracranial or systemic) of 15.9 months in the tucatinib arm versus 9.7 months in the control group (HR: 0.29) [67].”
InfluentialPeng, J., Chen, Q., Liu, L., Xie, N., Liu, M., Liu, X. E., Qian, L., Lu, K., Wu, T., Xie, H., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251387965 · Cited by 2
Sarfraz, Z., Ozair, A., Bardhan, M., Starosciak, A. K., Perche, D. C., Hodgson, L. C., Odia, Y., Mehta, M. P., Kotecha, R. R., McDermott, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-15224-3 · Cited by 2
“The 12-month intracranial PFS was nearly 59%, and the CNS objective response rate exceeded 70% in patients with measurable lesions, establishing it as a promising option in this setting [13].”
InfluentialBorrego, M. R., Páez, D., Vila, M. M., Pérez-García, J. M., Fernández-Abad, M., Tormo, S. B., García-Sáenz, J. Á., Lema, L., Garau, I., Cortez, P., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116161 · Cited by 2
Gautam, M., Kumar, C. D., Ramachandran, P., Kumar, A., Gopalsamy, I. K., Swaminathan, G., Cordani, M., & Kumar, L. D. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178446 · Cited by 3
Kubeczko, M., d’Amico, A., Chrabański, O., Handkiewicz-Junak, D., Polakiewicz-Gilowska, A., Swiderska, K., Mianowska-Malec, M., Leśniak, A., Lanoszka, B., Lisovska, N., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02191-7 · Cited by 2
“In parallel, central nervous system (CNS) involvement affects up to 50% of patients with HER2 + MBC. Tuca-tinib, a HER2-selective TKI with CNS activity, improved both PFS and OS in the HER2CLIMB trial [9], especially in patients with active brain metastases [10].”
Chmielewska-Krzesińska, M. (2026) · Animals · doi:10.3390/ani16020232 · Cited by 2
“In the HER2CLIMB trial (tucatinib, trastuzumab, and capecitabine), a toxicity profile dominated by diarrhoea, palmar-plantar erythrodysaesthesia, hepatotoxicity and gastrointestinal adverse events was seen [129].”
Valenza, C., Nixon, N. A., Cheung, W. Y., & Tolaney, S. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02942 · Cited by 2
Breast Cancer Brain Metastases: Current Understanding and Future Directions
Alabdulrahman, M., Daly, G. R., Naidoo, S., Stuart, L., Almasri, S. A., Benour, A., McGrath, J., Habaka, M., Dowling, G. P., Hehir, C. M., et al. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01753-y · Cited by 2
“This approval was based on the HER2CLIMB trial which found this drug combination to have a progression-free survival of 24.9% at one year compared to 0% of the placebo group in brain metastasis patients [106].”
InfluentialSong, P. N., Mansur, A., Gallegos, C., Ghanate, P., Lapi, S. E., & Sorace, A. G. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07936-2 · Cited by 2
“…has emerged as a critical agent in the treatment landscape of metastatic HER2 + breast cancer, particularly following the success of clinical trials, which demonstrated improved overall survival and intracranial response rates when tucatinib was combined with trastuzumab and capecitabine [14, 16].”
Suryawanshi, M. V., Girase, R. T., Bagul, V. S., & Gujarathi, P. P. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04331-7 · Cited by 2
Zhao, H., Wang, P., Jiao, Y., Huang, H., Yu, M., He, Q., Pan, C., Guo, S., Huang, W., Jia, Y., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199043 · Cited by 2
“Tucatinib is an oral, HER2-specific small-molecule tyrosine kinase inhibitor recently approved for the treatment of previously treated HER2-positive metastatic breast cancer and colorectal cancer (23–25).”
Suleiman, A. A., Quagliariello, V., Spadafora, L., Russo, F. Y., & Maurea, N. (2026) · Pharmaceuticals · doi:10.3390/ph19060833 · Cited by 3
“The HER2CLIMB trial reported excellent safety, with rare LVEF decline or ECG abnormalities [114].”
Akinnusi, P. A. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109288 · Cited by 2
Stereotactic radiosurgery in the treatment of adults with metastatic brain tumors
Eastman, B. M., Venur, V. A., Lo, S. S.-M., & Graber, J. J. (2020) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.20.04952-8 · Cited by 2
Weiss, J. A., Nicklawsky, A., Kagihara, J. A., Gao, D., Fisher, C. M., ELIAS, A. D., Borges, V. F., Kabos, P., Davis, S. L., Leong, S., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3487 · Cited by 2
Self-citationZhao, H., Ma, W., Fragoso, R. C., Harsh, G. R., Ashok, A., & Li, T. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.07.004 · Cited by 2
“Recently, HER2-targeted therapy has shown intracranial clinical activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer 3, 4 , but there is no effective systemic treatment for TNBC patients with BM.”
BackgroundRusso-Vorms, L., Astaras, C., Sandoval, J. L., Borgeaud, M., & Bodmer, A. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.09.044 · Cited by 2
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.